India wants to move from being a global generics hub to a leader in pharma innovation. From your vantage point in academia, what is holding that transition back?
With our vast talent base and premium manufacturing capacities we can accelerate our path to global leadership by actively tackling four foundational pillars in research and academia. A seamless, trust-based collaboration between industry and research institutions to fund frontier innovation, synergistic partnerships where industry confidently backs early-stage, visionary academic research is the need of hour. Simultaneously, academia can evolve its metrics of successmoving beyond publication counts to celebrate tangible outcomes like patent commercialisation, technology transfers, and thriving spin-offs that reward every contributor. We have a tremendous opportunity to scale up our R&D investment from the current 0.6 per cent to 0.7 per cent of GDP toward the two to three per cent benchmarks seen in nations like the US, China, and South Korea. Our academic laboratories are equipped with world-class capabilities in pharma, biopharma and molecular research. The next vital step is to surround our scientists with a robust translational ecosystem while simultaneously empowering senior faculty and institutional leaders to embrace this new era of commercialisation using industry norms of quality management system establishment in research laboratories. By pairing this infrastructure with more agile, modern regulatory pathways for advanced therapeutics and biologics, we can match the velocity of global innovation hubs like Boston or San Francisco and dramatically shorten the journey from the lab bench to the patient. This will develop a mature network of scientist-entrepreneurs who can successfully take a novel drug to market and can mentor the next generation so as to channel this immense intellectual capital into our own rapidly evolving innovation ecosystem.
Pharma companies are under pressure to innovate faster and manage R&D costs. What can academia realistically do to help industry solve problems faster?
To accelerate innovation and curb soaring R&D costs, academia and pharma companies can function as dynamic, agile research partners. Although, in realistic terms, universities may not keep up the pace and match the scale of industrial development, but they can fundamentally derisk the early stages of discovery. Embracing a culture of open innovation and pre competitive consortia academia can work with multiple pharma companies on shared, nonproprietary challenges. Implementing clear, prenegotiated, and industryfriendly licensing frameworks allows companies to quickly pick up academic discoveries and move them into pipeline development without legal friction. Replacing a publication first mindset to a patent and proof of concept validation will reduce target failure rates.
Instead of every pharma company investing in niche, expensive equipment universities can operate as centralised, state-of-the-art “core facilities” providing rapid testing services to industry partners at a fraction of the cost. Academia can co-design curriculum and PhD programs with industry inputs. Creating seamless pathways for academic faculty to spend sabbaticals inside pharma R&D labs-and vice versa-ensures that academic research stays aligned with actual, practical commercial bottlenecks.
There is still a gap between a promising academic discovery and something industry can develop at scale. Where does that gap usually emerge?
academic discovery and a scalable industrial product is known as the “Translational Valley of Death”. For instance, an academic lab might successfully synthesise milligrams of a complex molecule using expensive, lowyield, or highly toxic chemical steps while the industry requirement is in kilograms or tons produced via highly reproducible, safe, and costeffective processes. A compound that successfully kills cancer cells in a petri dish frequently fails inside a complex living organism. Academic researchers in India often lack the specialised resources to test Pharmacokinetics and Pharmacodynamics.
Industry requires data generated under strict Good Laboratory Practice (GLP) standards. When pharma companies attempt to replicate breakthrough academic findings under rigid industrial conditions, a startlingly high percentage of the results cannot be reproduced, killing the project instantly. While academia rewards novelty industry rewards clinical utility for a drug that is safer, cheaper, or easier to administer than what is already on the pharmacy shelf. The IP blind spot further gaps this valley because academic scientists often publish their findings too early and without an airtight patent protection, industry cannot justify spending hundreds of millions of dollars to bring the discovery to market.
NIPER was created to strengthen specialised pharma education and research. How do you see its role evolving as the industry moves towards complex generics, biologics, advanced drug delivery and other newer technologies?
As the Indian pharma sector transitions from volume-based traditional generics to a highvalue, innovation-driven biopharma powerhouse, the National Institute of Pharmaceutical Education and Research (NIPER) is shifting its core focus toward specialised R&D, advanced therapeutics, and industry collaboration. With national initiatives like the `10,000-crore biopharma manufacturing push, NIPER campuses are expanding infrastructure for noncommunicable diseases (such as cancer, diabetes, and autoimmune disorders) to build domestic expertise in biologics. Responding to specialised industrial demand, NIPER has integrated dedicated streams and testing infrastructure for medical device engineering and regulatory compliance. Moving away from routine manufacturing support, NIPER acts as an incubation and grantsupport hub for faculty-led and student-led deep-tech pharma startups. To catalyse the transition of NIPERs and the wider ecosystem toward complex therapeutics, the Government of India has deployed a multi-layered support architecture. These flagship initiatives directly bridge the gap between academic research, regulatory compliance, and commercial market entry. With a `5,000 crore total financial outlay, the PRIP scheme managed by the Department of Pharmaceuticals is the cornerstone of India’s innovation push. Allocates `700 crores to establish dedicated Centres of Excellence (CoEs) across all seven NIPER campuses. Each campus focuses on a specialised domain. A newly formed institutional bridge led by the Secretary of the Department of Pharmaceuticals. It brings together all major industry associations and NIPER heads to ensure academic curricula and research directly match the industry’s shift toward biologics and advanced engineering. By intentionally linking financial backing, infrastructure building, regulatory handholding, and intellectual property support, the framework targets the historical bottlenecks that previously slowed down Indian pharma innovation.
Coming to your own work, what is the specific problem your research is trying to solve, and why does it matter to patients or the pharma industry today?
My research focuses directly on bridging the gap between advanced formulation science and real-world execution, specifically within injectables and specialty formulations. In the current landscape, formulation is becoming the primary value driver and differentiator. My work focuses on designing future formulations that support selfadministration through wearable injectors, pre-filled syringes, and next-generation delivery systems. My dual role as a Scientist & Project Manager for the PRIP Centre of Excellence (CoE) in Medical Devices, combined with my credentials as an ISO 13485 Lead Assessor, allows me to bridge the critical gap between academic prototyping and global commercialisation under the guidance and visionary leadership at institute level. The primary reason many innovative medical device prototypes fail to reach the market is a lack of compliance with international Quality Management Systems (QMS). As a certified ISO 13485 Lead Assessor, I embed global compliance requirements directly into our scientific workflows. Establishing a Quality Management System (QMS) and securing NABL accreditation (ISO/IEC 17025:2017) for specialised testing laboratories is the definitive step in transforming a research laboratory into a globally recognised conformity assessment body. At the PRIP Centre of Excellence in Medical Devices at NIPER Ahmedabad, we executed this exact roadmap. The NIPER-A Testing Laboratory (NTL) achieved national milestone status as India’s first NABL-accredited facility for specialised mechanical orthopedic implant testing. I spearhead the establishment of our Quality Management System (QMS) and direct the end-to-end documentation pipeline required to secure NABL accreditations across our specialised mechanical, analytical, and biocompatibility testing laboratories. Ultimately, our goal at the CoE is to prove that when academic research embraces a rigorous, regulatoryfirst approach, it creates intellectual property that the pharma and MedTech industries can rapidly scale, commercialise, and bring directly to patients.
When research moves closer to commercialisation, what tends to become the biggest challenge-funding, scale-up, validation, regulatory requirements or finding the right industry partner?
Moving research out of the lab and into the market-a risky transition known as the “Valley of Death”-presents a complex web of hurdles rather than a single isolated challenge. While the exact bottleneck varies by sector, deep-tech and science-based innovations are primarily choked by regulatory compliance and validation, where navigating rigorous FDA/EMA approvals and multi-phase clinical trials requires years of effort and carries the highest risk of failure. Furthermore, companies must conquer industrial scale-up by translating delicate lab protocols into stable, costeffective manufacturing processes, while simultaneously achieving market validation by securing channel partners or enterprise customers to prove the scientific breakthrough solves a genuine, profitable problem.
If you could change one thing about the way Indian academia and pharma industry work together today, what would you change-and what difference could that make to India’s innovation ambitions?
Evolve a co-owned, codelivered, and co-evaluated translation models by expanding the policies that allow academic researchers and professors to actively spin off or lead commercial ventures while retaining institutional ties. By implementing flexible, tiered licensing agreements allows industry partners to take commercial risks while ensuring universities receive fair royalties and empowering scientists to transition smoothly between teaching and industry roles creates a dynamic exchange of ideas and upskilling.
lakshmipriya.nair@expressindia.com
laxmipriyanair@gmail.com